Our in vitro and in vivo results indicated that co-targeting the CXCR2 proangiogenic cytokine axis with anti-VEGF inhibition is an effective strategy to provide extended therapeutic benefits in pre-clinical models of ovarian cancer. Here, CXCR2 is linked to ovarian cancer.